Effects of antiviral therapy for hepatitis C following treatment of hepatocellular carcinoma: survey findings of the Japanese Red Cross Liver Study Group

Joko, Kouji; Goto, Tetsuhiro; Watanabe, Hiroshi; Mitsuda, Akari; Uchida, Yasushi; Hasebe, Chitomi; Tsuruta, Shotaro; Kimura, Hiroyuki; Koike, Toshiyuki; Akamatsu, Takuji; Mashiba, Toshie; Ochi, Hironori; Nakamura, Yoshiko; Tsuchiya, Kaoru; Kurosaki, Masayuki; Izumi, Namiki

doi:10.1111/hepr.12515

Cited by 12 publications

(19 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…From 858 unique results identified from our initial search strategy, the manuscripts of 45 potentially relevant abstracts were reviewed in full detail. Ten studies (all cohort studies) reporting on the association between SVR and outcomes in patients with HCV infections after local therapies for HCC were selected . HRs in two of these studies were obtained by correspondence with the authors .…”

Section: Resultsmentioning

confidence: 99%

Impact of sustained viral response postcurative therapy of hepatitis C‐related hepatocellular carcinoma: a systematic review and meta‐analysis

Manthravadi

Paleti

Pandya

2016

Intl Journal of Cancer

View full text Add to dashboard Cite

Antiviral therapy with interferon based therapies (IBT) has shown potential in improving survival in patients who have undergone resection or locoregional therapy for hepatitis C-associated hepatocellular carcinoma (HCV-HCC). However, this benefit has not been definitively ascribed to sustained viral response (SVR). Since IBT has been replaced with new directly acting agents (DAA), which are more efficacious in the treatment of HCV, we sought to better determine the prognostic impact of SVR in HCV-HCC. A systematic search of MEDLINE and EMBASE from inception through October 2015 was performed to identify studies that described the impact of presence of SVR in patients who underwent curative treatment of HCV-HCC. Summary hazard ratio (HR) with 95% confidence intervals (CI) was estimated for recurrence-free survival (RFS) and overall survival (OS) utilizing a random-effects model. After reviewing 858 abstracts, ten studies which included a total of 1,794 patients were selected and data was extracted. Of these ten studies, the impact of SVR on RFS and OS was reported in eight and seven studies respectively. In a meta-analysis which included 1,519 patients, SVR was associated with improved OS (HR 0.18; 95% CI 0.11-0.29, I = 2%). We also found that SVR was associated with better RFS in a meta-analysis (1,241 patients; HR 0.50; 95% CI 0.40-0.63, I = 0). In conclusion, SVR is associated with improved OS and RFS in patients with HCV who have undergone resection or locoregional therapy for HCC. Newer DAA therapies which offer increased tolerability and viral eradication should be considered as adjunctive therapy.

show abstract

Section: Resultsmentioning

confidence: 99%

Impact of sustained viral response postcurative therapy of hepatitis C‐related hepatocellular carcinoma: a systematic review and meta‐analysis

Manthravadi

Paleti

Pandya

2016

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…Chronic hepatitis virus infection can lead to persistent hepatic inflammation and liver fibrosis, which may further result in a higher tumor recurrence rate and inferior liver function reserve. 33 As it was suggested by several authors that antiviral therapies after hepatectomy may influence the recurrence rate as well as the OS of patients with HCC, [33][34][35][36] it would be interesting to evaluate the prognostic value of postoperative antiviral therapies in our cohort. To our regret, due to the retrospective nature of the study, we failed to obtain the detailed data regarding antiviral therapy following hepatectomy in these patients; this factor will be taken into consideration in our future study design.…”

Section: Discussionmentioning

confidence: 99%

Prognostic value of the albumin–bilirubin grade in patients with hepatocellular carcinoma: Validation in a Chinese cohort

Zhao

et al. 2016

Hepatology Research

View full text Add to dashboard Cite

show abstract

“…This nationwide observational multicenter study was undertaken by the Japanese Red Cross Liver Study Group, including 24 centers of Japanese Red Cross Hospitals. Previously, we reported that the overall SVR rate for GT2 patients treated with SOF + RBV was 96.8% in a multicenter cohort .…”

Section: Methodsmentioning

confidence: 99%

Efficacy and safety of glecaprevir/pibrentasvir as retreatment therapy for patients with genotype 2 chronic hepatitis C who failed prior sofosbuvir plus ribavirin regimen

Kusakabe

Kurosaki

Itakura

et al. 2019

Hepatology Research

Self Cite

View full text Add to dashboard Cite

Aim Rescue therapy for patients with genotype 2 (GT2) chronic hepatitis C who failed prior sofosbuvir (SOF) plus ribavirin (RBV) awaits establishment. This study aims to investigate the efficacy and safety of the fixed‐dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) (GLE/PIB) for patients with GT2 chronic hepatitis C. Methods In this nationwide observational study undertaken by the Japanese Red Cross Liver Study Group, 28 GT2 patients with prior failure of SOF + RBV were retreated with GLE/PIB for 12 weeks. We evaluated the rate of sustained virologic response (SVR) and adverse events. Results After 4 weeks of therapy, serum hepatitis C virus RNA was below the limit of quantification in all patients. The SVR after 4 and 12 weeks of the end of treatment was validated in 100% (28/28) and 100% (28/28), respectively. The adverse events comprised pruritus (eight patients), fatigue (four patients), and appetite loss (four patients), all of which were mild in severity. Conclusions This study establishes the efficacy of GLE/PIB as retreatment in Japanese patients with GT2 chronic hepatitis C not responding to SOF + RBV.

show abstract

Effects of antiviral therapy for hepatitis C following treatment of hepatocellular carcinoma: survey findings of the Japanese Red Cross Liver Study Group

Cited by 12 publications

References 25 publications

Impact of sustained viral response postcurative therapy of hepatitis C‐related hepatocellular carcinoma: a systematic review and meta‐analysis

Impact of sustained viral response postcurative therapy of hepatitis C‐related hepatocellular carcinoma: a systematic review and meta‐analysis

Prognostic value of the albumin–bilirubin grade in patients with hepatocellular carcinoma: Validation in a Chinese cohort

Efficacy and safety of glecaprevir/pibrentasvir as retreatment therapy for patients with genotype 2 chronic hepatitis C who failed prior sofosbuvir plus ribavirin regimen

Contact Info

Product

Resources

About